Cripto antagonism of activin and TGF-b signaling

Details Cripto antagonism of activin and TGF-b signaling Cripto antagonism of activin and TGF-b signaling

2004-09-14

2010-10-26

Skelding, Zachary (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07820620

ABSTRACT:
Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.

REFERENCES:
patent: 5792616 (1998-08-01), Persico et al.
patent: 5854399 (1998-12-01), Salomon et al.
patent: 7297478 (2007-11-01), Reinl et al.
patent: 2001/0036635 (2001-11-01), Waldmann et al.
patent: WO 94/11502 (1994-05-01), None
patent: WO 02/22808 (2002-03-01), None
patent: WO 02/077033 (2002-10-01), None
patent: WO 02/088170 (2002-11-01), None
patent: WO 03/083041 (2003-10-01), None
patent: WO 2004/083375 (2004-09-01), None
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Attwood, Science 290: 471-473, 2000.
Skolnick et al., Trends in Biotechnology 18: 34 39, 2000.
Harrison CA et al., J Biol Chem. Jun. 6, 2003;278(23):21129-35.
Rebbapragada A et al., Mol Cell Biol. Oct. 2003;23(20):7230-42.
Harrison CA et al., Trends Endocrinol Metab. Mar. 2005;16(2):73-8.
Cheng SK et al., Genes Dev. Jan. 1, 2003;17(1):31-6.
Harrison CA et al., J Biol Chem. Jul. 2, 2004;279(27):28036-44.
Gray et al., Mol Cell Biol. Dec. 2006;26(24):9268-78.
Adkins et al., J Clin Invest. Aug. 2003;112(4):575-87.
Javelaud et al., Oncogene. Nov. 17, 2005;24(51):7624-9.
Suzuki et al., Clin Cancer Res. Sep. 1, 2004;10(17):5907-18.
Kelber et al., J Biol Chem. Dec. 18, 2007.
Slawomir Wojtowicz-Praga, Invest New Drugs. Feb. 2003;21(1):21-32.
Sonia Jakowlew, Cancer Metastasis Rev. Sep. 2006;25(3):435-57.
Randall Brand, Cancer J. Jul.-Aug. 2001;7(4):287-97.
Genbank accession No. Z22536, Feb. 10, 1999.
Risbridger et al., Mol Cell Endocrinol. Jun. 30, 2001;180(1-2):149-53.
Fawcett et al., The Journal of Cell Biology, vol. 128, 1995.
Adkins et al., J. Clin. Invest. 112:575-587 (2003).
Michael Shen, J. Clin. Invest. 112:500-502 (2003.
Supplementay European Search Report, issued in European Application No. EP04783979, dated Feb. 22, 2008.
Attisano et al., “Identification of human activin and TGFBETA type I receptors that form hetermeric kinase complexes with type II receptors,”Cell,75:671-680, 1993.
Dijke et al., “Activin receptor-like kinases: A novel subclass of cell-surface receptors with predicted serine/threonine kinase activity,”Oncogene,8(10):2879-2887, 1993.
Gray et al., “Cripto forms a complex with activin and type II activin receptors and can block activin signaling,”Proceedings of the National Academy of Sciences of the United States of America,100(9):5193-5198, 2003.
Mathews, “Activin receptors and cellular signaling by the receptor serine kinase family,”Endocrine Reviews,15(3):310-325, 1994.
Partial European Search Report, issued in European Patent application No. 09009758.5, dated May 10, 2010.
Schiffer et al., “Fucosylation of cripto is required for its ability to facilitate nodal signaling,”The Journal of Biological Chemistry, 276(41):37769-37778, 2001.
Yan et al., “Dual roles of cripto as a ligand and coreceptor in the nodal signaling pathway,”Molecular and Cellular Biology, 22(13):4439-4449, 2002.
Yeo and Whitman, “Nodal signals to Smads through cripto-dependent and cripto-independent mechanisms,”Molecular Cell, 7:949-957, 2001.

Affiliated with

Also associated with

Rating

Cripto antagonism of activin and TGF-b signaling does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cripto antagonism of activin and TGF-b signaling, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cripto antagonism of activin and TGF-b signaling will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4181623